Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States-Reference-Cited by-同舟云学术

Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States

Published:2019-01-11 Issue:7 Volume:60 Page:1668-1676
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Guzauskas Gregory F.¹^ORCID,Masaquel Anthony²,Thuresson Per-Olof³,Dawson Keith²,Veenstra David L.¹

Affiliation:

1. Department of Pharmacy, University of Washington, Seattle, WA, USA;

2. Genentech, Inc., South San Francisco, CA, USA;

3. F. Hoffmann-La Roche Ltd., Basel, Switzerland

Funder

Genentech, Inc

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1551532

Reference29 articles.

1. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

2. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

3. Non-Hodgkin Lymphoma: Diagnosis and Treatment

4. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma;Journal of Managed Care & Specialty Pharmacy;2021-05

2. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany;Journal of Comparative Effectiveness Research;2020-10

3. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients;Journal of Medical Economics;2020-07-23

4. Answer to Simulation Analysis of Cost-Effectiveness in 2012 Has Finally Come in 2019;Journal of Clinical Oncology;2020-02-10

5. Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond;EMJ Hematology;2015-07-30